TIMI 12

TIMI 12 evaluated the safety and efficacy of the oral GP IIb/IIa inhibitor sibrafiban for the treatment of patients with a recent acute coronary syndrome.

MAIN RESULTS:
Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial

Circulation. 1998 Feb 3;97(4):340-9.

PRESENTATIONS

TIMI 12 Slides

OTHER PUBLICATIONS

Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Mar;33(3):634-9.

Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov;25(22):1998-2005.

Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005 Apr 26;111(16):2042-9.

Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich). 2006 May;8(5):315-22.

The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2008 Dec 17;131(1):105-12.